We are live on ! Find out more
IC

Ikarian Capital Portfolio holdings

AUM $1.23B
1-Year Est. Return 600.17%
This Fund
S&P 500
This Quarter Est. Return
+34.92%
1 Year Est. Return
+600.17%
3 Year Est. Return
+5,763.15%
5 Year Est. Return
+15,527.6%
10 Year Est. Return
–
AUM
$1.07B
AUM Growth
+$237M
Cap. Flow
+$422M
Cap. Flow %
39.55%
Top 10 Hldgs %
35.09%
Holding
191
New
51
Increased
37
Reduced
12
Closed
55

Top Buys

Rank Stock Value
1
ARGX icon
argenx
ARGX
+$32.6M
2
XHB icon
State Street SPDR S&P Homebuilders ETF
XHB
+$16.3M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$13.4M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$12.7M
5
ALPN
Alpine Immune Sciences Inc
ALPN
+$6.77M

Top Sells

Rank Stock Value
1
AKRO
Akero Therapeutics
AKRO
+$10.1M
2
RCKT icon
Rocket Pharmaceuticals
RCKT
+$9.16M
3
SLRN
ACELYRIN
SLRN
+$7.92M
4
PCVX icon
Vaxcyte
PCVX
+$7.26M
5
GPCR icon
Structure Therapeutics
GPCR
+$7.07M

Sector Composition

Rank Sector Weight
1 Healthcare 31.68%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATXS
76
DELISTED
Astria Therapeutics
ATXS
$2.88M 0.27%
374,807
– –
LRMR icon
77
Larimar Therapeutics
LRMR
$397M
$2.74M 0.26%
602,868
-80,000
-12% -$270K
IMGN
78
DELISTED
Immunogen Inc
IMGN
$2.67M 0.25%
90,162
-300,000
-77% -$5.97M
VYGR icon
79
Voyager Therapeutics
VYGR
$183M
$2.58M 0.24%
305,857
– –
SLRN
80
CALL
DELISTED
ACELYRIN
SLRN
$2.51M 0.24%
336,900
+335,531
+24,509% +$2.86M
CYTK icon
81
Cytokinetics
CYTK
$10.5B
$2.5M 0.23%
+30,000
New +$1.09M
MRNA icon
82
Moderna
MRNA
$21.8B
$2.44M 0.23%
+24,546
New +$2.06M
DFTX
83
Definium Therapeutics
DFTX
$5.78B
$2.2M 0.21%
+600,000
New +$1.81M
APLS
84
DELISTED
Apellis Pharmaceuticals
APLS
$2.06M 0.19%
+34,361
New +$1.74M
TARS icon
85
CALL
Tarsus Pharmaceuticals
TARS
$2.58B
$2.02M 0.19%
+100,000
New +$1.67M
AEON icon
86
AEON Biopharma
AEON
$12.9M
$1.86M 0.17%
3,583
– –
NUVB icon
87
Nuvation Bio
NUVB
$2.2B
$1.85M 0.17%
1,222,852
– –
OKUR
88
CALL
OnKure Therapeutics
OKUR
$154M
$1.73M 0.16%
+108,260
New +$6.75M
ROIV icon
89
Roivant Sciences
ROIV
$24.5B
$1.7M 0.16%
151,821
+150,000
+8,237% +$1.46M
AUTL
90
Autolus Therapeutics
AUTL
$407M
$1.69M 0.16%
262,694
– –
BDTX icon
91
Black Diamond Therapeutics
BDTX
$96.8M
$1.56M 0.15%
555,572
– –
RAPT
92
PUT
DELISTED
RAPT Therapeutics
RAPT
$1.46M 0.14%
+7,350
New +$910K
KOD icon
93
Kodiak Sciences
KOD
$2.6B
$1.26M 0.12%
412,881
+100,000
+32% +$222K
ABOS icon
94
Acumen Pharmaceuticals
ABOS
$155M
$1.21M 0.11%
315,265
– –
CRBP icon
95
Corbus Pharmaceuticals
CRBP
$166M
$1.18M 0.11%
195,899
– –
CHRS icon
96
Coherus Oncology
CHRS
$217M
$1.13M 0.11%
340,787
-525,000
-61% -$1.41M
IFRX icon
97
InflaRx
IFRX
$250M
$1.12M 0.11%
688,604
– –
TERN
98
DELISTED
Terns Pharmaceuticals
TERN
$1.07M 0.1%
165,480
– –
QURE icon
99
uniQure
QURE
$3.03B
$1.07M 0.1%
157,365
– –
ESPR
100
DELISTED
Esperion Therapeutics
ESPR
$1.01M 0.09%
337,636
-1,400,000
-81% -$1.82M
2 3
4
5 6

Similar funds

FLII
First Long Island Investors Jericho, New York $1.23B AUM 14.42% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
HCA
Harbor Capital Advisors Chicago, Illinois $1.23B AUM 30.56% 1-Year Est. Return
GX
Greylock XIV Menlo Park, California $1.24B AUM
WCM
Windward Capital Management Los Angeles, California $1.23B AUM 23.17% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.24B AUM 41.74% 1-Year Est. Return
IA
Inspire Advisors Meridian, Idaho $1.23B AUM 18.62% 1-Year Est. Return
IB
Intrust Bank Wichita, Kansas $1.23B AUM 26.34% 1-Year Est. Return

Ikarian Capital's Q4 2023 Portfolio in Review

As of Q4 2023, Ikarian Capital held 191 positions worth $1.07B, up 28% from $831M the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Ikarian Capital deployed $422M of net new capital in Q4 2023, opening 51 new positions and adding to 37 existing holdings. Its largest new stake was argenx: 70,000 shares worth $26.5M.

By sector, the portfolio is most concentrated in Healthcare at 32% of assets, up from 32% a quarter earlier.

On the sell side, the largest reduction was Rocket Pharmaceuticals, an estimated $9.16M trimmed.

  • Ikarian Capital's largest Q4 2023 buy was argenx: 70,000 shares worth $26.5M.
  • Ikarian Capital added most to Disc Medicine in Q4 2023, an estimated $2.67M increase.
  • Ikarian Capital's biggest Q4 2023 reduction was Rocket Pharmaceuticals, cutting an estimated $9.16M.
  • Ikarian Capital fully exited Akero Therapeutics in Q4 2023, selling an estimated $10.1M.
  • Ikarian Capital's ten largest holdings make up 35% of its $1.07B portfolio in Q4 2023.
  • Ikarian Capital opened 51 new positions and closed 55 in Q4 2023.
  • Ikarian Capital's portfolio value rose 28% quarter-over-quarter to $1.07B.

Based on Ikarian Capital's 13F filing for Q4 2023, filed 14 Feb 2024.